BACKGROUND: There is little consensus on a standard approach to analysing bone scan images. The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but the popularity of this metric is hampered by the tedium of the manual calculation. OBJECTIVE: Develop a fully automated method of quantifying the BSI and determining the clinical value of automated BSI measurements beyond conventional clinical and pathologic features. DESIGN, SETTING, AND PARTICIPANTS: We conditioned a computer-assisted diagnosis system identifying metastatic lesions on a bone scan to automatically compute BSI measurements. A training group of 795 bone scans was used in the conditioning process. Independent validation of the me...
BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utilit...
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden...
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) ...
BACKGROUND: There is little consensus on a standard approach to analysing bone scan images. The Bone...
Prostate cancer (PCa) is one of the most common diseases in the world. PCa can primarily disseminate...
Contains fulltext : 233937.pdf (Publisher’s version ) (Closed access)BACKGROUND: O...
INTRODUCTION The bone scan index (BSI) was introduced as a quantitative tool for tumor involvemen...
Background: Metastatic castration resistant prostate cancer (mCRPC) is a bone dominant lethal diseas...
BACKGROUND: The objective of this study was firstly to develop and evaluate an automated method for ...
A bone scan is a common method for monitoring bone metastases in patients with advanced prostate can...
INTRODUCTION: The bone scan index (BSI) was introduced as a quantitative tool for tumor involvemen...
Abstract Background The purpose of this study was to compare the agreement of the bone scan index (B...
Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have...
Analysis of regional bone scan index measurements for the survival of patients with prostate cancer ...
IMPORTANCE Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pa...
BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utilit...
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden...
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) ...
BACKGROUND: There is little consensus on a standard approach to analysing bone scan images. The Bone...
Prostate cancer (PCa) is one of the most common diseases in the world. PCa can primarily disseminate...
Contains fulltext : 233937.pdf (Publisher’s version ) (Closed access)BACKGROUND: O...
INTRODUCTION The bone scan index (BSI) was introduced as a quantitative tool for tumor involvemen...
Background: Metastatic castration resistant prostate cancer (mCRPC) is a bone dominant lethal diseas...
BACKGROUND: The objective of this study was firstly to develop and evaluate an automated method for ...
A bone scan is a common method for monitoring bone metastases in patients with advanced prostate can...
INTRODUCTION: The bone scan index (BSI) was introduced as a quantitative tool for tumor involvemen...
Abstract Background The purpose of this study was to compare the agreement of the bone scan index (B...
Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have...
Analysis of regional bone scan index measurements for the survival of patients with prostate cancer ...
IMPORTANCE Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pa...
BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utilit...
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden...
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) ...